We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton (BDX) Beats on Q1 Earnings and Revenues Estimates
Read MoreHide Full Article
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #2 (Buy) but that could change following its first-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.48 per share beat the Zacks Consensus Estimate of $2.40 and increased 3.9% at constant currency (cc) basis.
Becton, Dickinson and Company Price and EPS Surprise
Revenues: Reported revenues amounted to $3.08 billion up 3.7% at cc. Revenues also came above the Zacks Consensus Estimate of $3.05 billion.
Key Stats: For fiscal 2018, revenues, including the accretion from the acquisition of C.R. Bard, are expected to increase approximately 30 to 31% at cc.
The company also expects adjusted diluted earnings per share to be between $10.85 and $11, which represents a growth of approximately 12% at cc, including the accretion from the acquisition of C.R. Bard.
Major Factors: BD Medical generated revenues of $2.04 billion, up 1.9% at cc.
BD Life sciences generated revenues of $ 1.05 billion, up 7.3% at cc.
Stock Price: Shares have risen roughly 13.7% in the last six months, while the broader industry has gained 9.8% over the same time frame. However, following the earnings release, share prices decreased 0.4% in the pre-market trading session.
Check back later for our full write up on this Becton, Dickinson and Company earnings report!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Becton (BDX) Beats on Q1 Earnings and Revenues Estimates
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #2 (Buy) but that could change following its first-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.48 per share beat the Zacks Consensus Estimate of $2.40 and increased 3.9% at constant currency (cc) basis.
Becton, Dickinson and Company Price and EPS Surprise
Becton, Dickinson and Company Price and EPS Surprise | Becton, Dickinson and Company Quote
Revenues: Reported revenues amounted to $3.08 billion up 3.7% at cc. Revenues also came above the Zacks Consensus Estimate of $3.05 billion.
Key Stats: For fiscal 2018, revenues, including the accretion from the acquisition of C.R. Bard, are expected to increase approximately 30 to 31% at cc.
The company also expects adjusted diluted earnings per share to be between $10.85 and $11, which represents a growth of approximately 12% at cc, including the accretion from the acquisition of C.R. Bard.
Major Factors: BD Medical generated revenues of $2.04 billion, up 1.9% at cc.
BD Life sciences generated revenues of $ 1.05 billion, up 7.3% at cc.
Stock Price: Shares have risen roughly 13.7% in the last six months, while the broader industry has gained 9.8% over the same time frame. However, following the earnings release, share prices decreased 0.4% in the pre-market trading session.
Check back later for our full write up on this Becton, Dickinson and Company earnings report!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>